Patents Granted
We hold U.S. Patent No. 11,517,523, which covers both the formulation and method of use. Our intellectual property is protected in key global markets, including the EU, Canada, China, India, Australia, and Japan.
Patent Applications
We have filed provisional patents that expand the protection of
MX-0024 for use in animal health, specifically as an antiviral additive in feed or drinking water.
Patent Filing Strategy
Our strategic filings span over 20 countries, safeguarding MX-0024 for both human and veterinary applications across global markets.
Our development of MX-0024 is grounded in rigorous scientific research and clinical methodology.
Initial in-vitro studies demonstrated over 99% viral load reduction against Influenza A (H1N1) with no cytotoxicity observed.
Preclinical trials are underway, including upcoming mouse studies and a large-scale poultry trial involving 100,000 chickens to assess transmission prevention for H5N1 Avian Flu.
Planned Phase 1 human safety trials will follow, with a focus on evaluating real-world infection prevention outcomes.
Our development of MX-0024 is grounded in rigorous scientific research and clinical methodology.
Trust in our collaborative approach and let us demonstrate why our team is the perfect partner for your success.
